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Aim: To investigate treatment-related pain and the accuracy of navigated laser photocoagulation 
in the treatment of clinically significant macular edema.
Methods: Focal laser treatment of diabetic macular edema in 54 consecutive patients was 
digitally planned on fundus images and performed using the navigated laser photocoagulation 
system Navilas® (OD-OS GmbH, Teltow, Germany). Treatment-related pain was quantified 
on a visual analog scale directly after treatment and compared with a matched control group 
who received conventional laser treatment (n = 46). In addition, for Navilas-treated patients, 
the accuracy of spot placement on color images was analyzed 1 month after treatment.
Results: In total, 5423 laser spots (mean 100 per eye) were analyzed. With navigated   treatment, 
90% of laser spots were visible on color images, of which 96% were within 100 µm from the 
target. Eighty percent of the laser spots were placed and visible within the 100 µm target on 
an intention-to-treat basis for color imaging. Optical coherence topography confirmed that 
laser effects were limited to the outer retina. Treatment-related pain following navigated laser 
photocoagulation was significantly lower than that of conventional laser treatment (1.6 vs 4.4 
on a visual analog scale, P , 0.001).
Conclusion: Navigated laser effects could be visualized to a high percentage on post-treatment 
color images, and their location showed a high concordance to targeted areas. Patients reported 
that treatment-related pain following Navilas laser photocoagulation was significantly lower 
than pain following conventional laser treatment.
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Introduction
Diabetic retinopathy (DR) is the most frequent cause of new cases of blindness among 
adults of working age.1 Diabetic retinopathy can cause vision loss through several 
mechanisms, with diabetic macular edema (DME) being a major cause.2,3
Laser photocoagulation has played a central role in the treatment of both DR and 
DME in the past 30 years. The Diabetic Retinopathy Study (DRS) in 1971 marked 
the progression of photocoagulation clinical trials, which involved more than 
1700 patients enrolled across 15 medical centers. A significant result of the DRS and 
other population-based studies (such as the Early Treatment of Diabetic   Retinopathy 
Study) was the demonstration that retinal laser photocoagulation was a safe and 
  effective treatment for both DR and DME. Since then, laser photocoagulation has 
become a well-established standard therapy for DME, and it has recently been sup-
plemented by pharmacological interventions, particularly anti-vascular endothelial 
growth factor treatment.4
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Meyer-Schwickerath introduced retinal photocoagulation 
therapy in the 1950s using the xenon arc photocoagulator, 
and Campbell et al first described successful retinal laser 
photocoagulation in 1964 – a tremendous evolution of 
retinal laser therapy has taken place since this time.5,6 Most 
importantly, we have seen photocoagulation become a less 
painful and more accurate treatment of retinal diseases, and 
several technical advances have been introduced to laser 
therapy including subthreshold techniques7 and pattern 
laser generation.8 However, the advantages of computer-
ized precision (“eye tracking”) known from, eg, refractive 
surgery, have not become available despite several technical 
approaches towards that goal.9 Of note, in DME a protocol 
targeting microaneurysms appears to be advantageous versus 
a non-targeted early treatment diabetic retinopathy study 
(ETDRS) laser protocol,10 which may hint the importance 
of targeting precision when performing laser treatments. In 
addition, essential diagnostics for the planning of laser treat-
ment, such as fluorescein angiography, were mostly separated 
from the actual treatment device until the development of the 
navigated laser photocoagulation system Navilas® (OD-OS 
GmbH, Teltow, Germany).
Navilas is a novel fundus imaging and laser treatment 
device that allows imaging (infrared, color, and fluorescein 
angiography) and integrated laser treatment of the retina. 
It includes pattern laser generation and a laser planning 
feature.11,12 Besides documentation, safety, and patient 
comfort, the main theoretical advantages of Navilas use lie 
in retina navigation, which may help to improve the clinical 
outcomes of laser treatment. In focal laser treatment, Navilas 
offers computerized image and target assistance systems, 
resulting in high precision and a theoretical reproducibility of 
60  –110 µm.13 The integration of diagnostic information into 
the device may help to overcome shortcomings during the 
process of transferring laser surgery protocols and potential 
loss of accuracy, helping retinal physicians to achieve better 
outcomes when treating their patients. An increase in patient 
comfort and reduction of treatment-related pain may also 
result from this novel technology.
We therefore investigated clinical in vivo accuracy and 
treatment-related pain in patients undergoing focal laser 
  treatment with the Navilas system for diabetic macular 
edema.
Methods
Navilas
The Navilas device and its operation have been described 
  elsewhere.11 In brief, Navilas combines imaging, laser 
  application planning, and laser treatment in a single 
  computer-controlled device. It fundamentally differs from 
most other laser devices by not being added to a slit lamp but is 
instead a scanning slit-based instrument: it uses   approximately 
25 images per second in imaging or treatment mode. For focal 
laser treatment, the field of view is 50°, and this is displayed on 
a monitor. The optical resolution of the instrument used in this 
study was 1280 × 1024 pixels resulting in 20–26 pixels/degree. 
Due to the slit-imaging principle, color images are obtained 
with high contrast and sharpness.13 Another difference to slit 
lamp-based laser devices is the touch-screen monitor used for 
imaging,   planning, and treating fundus changes. This allows 
the retina specialist to plan laser spots on the screen for focal 
treatments, and then apply semi-automated patterns and single 
spots as appropriate. The pre-planned targets are stabilized 
on the fundus and a pre-positioning mode is provided by 
the system that automatically advances the aiming beam 
from each pre-planned target to the next. For treatment, the 
surgeon actuates the laser manually after he or she has veri-
fied the target lock.
Patients treated with navigated laser 
photocoagulation
Consecutive patients were recruited from the outpatient clinic 
of the Department of Ophthalmology, Ludwig Maximilian 
University of Munich, Germany. Patients were included if 
they had diabetes (based on WHO criteria) and were eligible 
for focal laser treatment as defined by the ETDRS criteria. 
Written informed consent was obtained from all patients. 
The device was a fully CE-approved laser at the time of this 
study. The study conformed to the principles expressed in the 
Declaration of Helsinki, and approval was obtained from the 
Ludwig Maximilian University’s Institutional Review Board. 
Patients were excluded if they suffered from eye diseases 
involving the posterior pole other than diabetic retinopathy 
(such as age-related macular degeneration), but they were 
not excluded for media opacities.
imaging
Navilas imaging was performed with fully dilated pupils after 
the clinical examination and before laser therapy, and con-
sisted of taking and saving several color images. Color imag-
ing with Navilas was repeated 1 month after laser treatment 
and compared with pre-treatment images. Assessment of 
treatment success was performed by one experienced grader. 
Additionally, spectral domain optical coherence topography 
(SD-OCT) was performed 1 month after laser treatment 
(Heidelberg Engineering, Heidelberg, Germany).
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Laser planning and treatment
Laser planning and treatment was performed according to the 
ETDRS principles, not specifically targeting   microaneurysms. 
A color image was obtained with the Navilas device and used 
to plan laser spot treatments by applying automated patterns 
and single spots as appropriate on the color image, thus gen-
erating a detailed treatment plan (Figure 1). It took less than 
5 minutes to plan the treatment for each eye.
For laser application, a navigated, semi-automatic pattern 
laser application was conducted based on the treatment plan. 
Treatment spot size was always set at 100 µm, and the treat-
ment time per spot was 100 milliseconds. The power settings 
of the green (532 nm) frequency doubled neodymium-doped 
yttrium aluminium garnet (Nd:YAG) laser were adjusted 
manually from a standard 100 mW so that spots showed a 
moderate whitening. The pre-positioning mode was used 
to automatically advance the targeting aiming beam from 
each targeted retinal position to the next position after the 
aiming beam and pre-planned target were stabilized on the 
living fundus. The surgeon actuated the laser manually after 
verifying the target lock. An alternating infrared to color 
video fundus visualization mode was applied to allow post-
treatment observation of the retinal burn for 2–3 seconds 
after each application without patient discomfort.
Grading of images
The laser spots visible on the Navilas color images 1 month 
after treatment were compared to the laser treatment plan by 
overlaying the laser treatment plan with the post-treatment 
color image (Figure 2). The resulting image was post-processed 
using ImageJ (National Institutes of Health, Bethesda, MD) 
to improve the visibility of laser spots: the contrast was 
enhanced, the background reduced, and the image was 
zoomed to the region of interest. The post-processed images 
(Figure 2) were used to determine whether each treatment spot 
touched or overlapped the targeted 100 µm laser spot (this was 
given a binary result: “match” or “no match”). The SD-OCT 
images were investigated for changes in the inner retinal 
layers overlying the laser spots. All data were collected in a 
Microsoft Excel 2000 spreadsheet (Microsoft Corporation, 
Redmond, WA) and analyzed using SPSS software (v 17.0 
for Windows; IBM Corp, Armonk, NY).
Evaluation of treatment-related pain  
after Navilas treatment
Immediately after treatment, patients were asked to quan-
tify their pain on a visual analog scale (VAS; 0 = no pain; 
10 = very bad pain). To evaluate treatment-related pain after 
Navilas treatment versus conventional treatment, data were 
Figure 1 Pre-planned focal laser spots (small circles) in the Navilas® system on color image. The large circles indicate non-treatment zones.
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collected from the 54 patients treated with the Navilas system 
as well as from a matched control group of 46 subjects treated 
with a conventional laser (532 nm wave-length, VISULAS 
532s, Carl Zeiss Meditec AG, Jena, Germany; laser settings: 
100 mW power, 100 millisecond pulse duration, 100 µm 
spot size). All patients were treated for DME at the authors’ 
diabetes clinic during the same period. The two groups were 
analyzed and compared using SPSS software. For statistical 
testing, P , 0.05 was considered significant.
Results
In the Navilas group, mean HbA1C was 7.8% (±4.2 SD), 
while in the matched control group that received conventional 
laser treatment the mean HbA1C was 7.4 (±3.8 SD). Mean 
central retinal thickness (CRT) before treatment was 402 µm 
(±154 µm SD) in the Navilas group and 388 µm (±172 µm 
SD) in the control group.
Treatment-related pain after Navilas  
treatment
Patients who received Navilas treatment quantified post-
treatment pain on the VAS with a mean of 1.6 (SD = 1.0), 
significantly lower (P , 0.001) than for the control group which 
had a mean of 4.4 (SD = 1.8) (Figure 3). Significantly fewer 
(mean 43 ± 36, P , 0.001) laser spots were applied to patients in 
the conventional laser group than those in the Navilas group.
Figure 2 Pre-planned focal laser spots (circles) overlaid with post-processed color image 1 month after laser treatment with Navilas®.
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Accuracy of navigated retinal laser 
photocoagulation with Navilas
A mean of 100 ± 86 spots per eye were pre-planned for 
treatment in 54 patients. All patients had clinically sig-
nificant macular edema (as defined by the ETDRS) caused 
by type 2 diabetes. In total, 25 right and 29 left eyes were 
treated. The mean patient age was 61 ± 12 years. In total, 
5423 pre-planned laser spots were applied and analyzed, 
and no complications occurred. Of those laser spots, 4888 
(90%) were visible in the 1 month color images (analysis 
per-protocol, PP). Mean hit-rate of visible spots was 96%. 
On an intention-to-treat (ITT) analysis based on color image 
burn evaluation the hit-rate was 80% (Figure 4). Retinal OCT 
morphology of laser spots confirmed that laser lesions were 
limited to the outer retina, particularly the retinal pigment 
epithelium and photoreceptor layer (Figure 5).
Discussion
The ETDRS demonstrated the effectiveness of focal photo-
coagulation in eyes with macular edema.2 In macular laser 
photocoagulation (focal or modified grid), the main goal is 
to solve leakage arising from macular vessels by photoco-
agulating photoreceptors. This results in a reduced need for 
oxygen in the outer retina, allowing oxygen to diffuse from 
the choroid to the inner retina, so reducing hypoxia.14 In 
addition, increased oxygen tension in the inner retina helps 
to decrease tissue edema and improve vision by autoregula-
tory vasoconstriction and reduced hydrostatic pressure in the 
capillaries and venules.14,15 Therefore, focal photocoagula-
tion, recently supplemented by treatments such as vascular 
endothelial growth factor treatment, is still the standard 
treatment. Nevertheless, in combined treatment, the use of 
modified laser protocols seems to be advantageous,4 and these 
data underscore the importance of precision laser targeting. 
Moreover, inadequate application of macular laser photoco-
agulation may be associated with loss of vision, diminished 
visual field, increased scotoma, reduced color vision, and 
reduced contrast sensitivity.16,17
The present study investigated the clinical accuracy 
of focal retinal laser application using a navigated, semi-
automatic pattern laser. By utilizing computerized laser sur-
geon support, a 96% hit rate was achieved on an analyzable 
(“per-protocol”) basis and 80% on an ITT basis. A target 
size of 100 µm spots was applied to all patients, demonstrat-
ing the device’s high laser spot application accuracy. The 
study does have some shortcomings such as missing clinical 
outcome data, a lack of follow-up, and a limited number of 
patients. It is also noted that the computerized laser surgeon 
support systems such as Navilas’s pre-positioning mode, 
target stabilization, and target assistance require complex 
and fast real-time image processing, which may result in 
errors. Although those occurred rarely in our patient series, 
the final actuating of the laser needs to be performed by the 
surgeon. In addition, it is possible to continue with manual 
treatment as a fallback in case the electronic systems do not 
operate adequately.
The strengths of the system include image quality and 
remarkable laser spot accuracy on an ITT basis, especially 
given the limited evaluation properties of color images 
per se. Still, the present study’s results demonstrate the 
high accuracy of the Navilas system. The authors believe 
that the current study demonstrates for the first time that 
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Figure 3 Patient’s treatment-related pain after navigated focal laser therapy with Navilas® was quantified by using a VAS.
Abbreviations: SD, standard deviation; VAS, visual analog scale.
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Figure 4 Accuracy of in vivo Navilas® treatment based on n = 54 and 100 ± 86 spots per patient. in total, 5423 pre-planned laser spots were applied and analyzed. Of those 
laser spots, 4888 (90%) were visible in the 1 month color images. The mean hit-rate of visible spots (color imaging) was 80% on an intention-to-treat (iTT) basis and 96% 
on a per-protocol (PP) basis.
Figure 5 Example of the retinal optical coherence topography morphology of laser spots.
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100 µm pre-defined targets can be hit in vivo with very high 
precision by a navigated laser system. In an independent 
study, Kozac et al showed similar results targeting retinal 
microaneurysms with the device.18 The clinical value of 
targeting micronaneurysms in DME is disputed,10 but this 
technique may provide data on accuracy as they are ana-
tomical landmarks on the fundus. In contrast to the work 
by Freeman’s group we measured the device’s ability to 
hit predefined fundus spots, which demonstrates accuracy 
with a given size target. While this approach has higher 
image processing requirements, it can be more universally 
applied to other diseases than DME, where improvements in 
accuracy may also have value, such as in venous occlusions 
or age-related macular degeneration. Navilas may serve as 
a platform for the development of new technology and its 
application in the treatment of those diseases or in special 
laser applications, such as subthreshold technology.
Patients suffering from DME do not always respond 
sufficiently to focal laser photocoagulation, which may be 
because laser treatment cannot always meet the patient’s 
medical requirements. There are many reasons for this, but 
it appears to be quite common for patients not to accept or 
understand the need for laser treatment, and many report 
that treatment is uncomfortable or painful. The tracking of 
pain has been found to be a helpful diagnostic tool when 
evaluating the patient’s treatment-related pain.19,20 By using 
a VAS the patient bypasses the cognitive level of the brain, 
resulting in a truer representation of pain.19,20
In our study, patients were asked to quantify treatment-
related pain by using a VAS, and those who received 
navigated focal laser photocoagulation rated this as signifi-
cantly less painful than conventional slit lamp-based laser 
photocoagulation (1.6 vs 4.4 respectively on a scale from 1 
[no pain] to 10 [very strong pain]). This implicates another 
potential advantage of navigated laser therapy with Navilas, 
and the use of devices such as this may result in better patient 
compliance and acceptance of this treatment option.
In summary, this paper presents data that demonstrates that 
the Navilas system is accurate when targeting predefined tar-
gets in vivo in DME focal laser therapy. This not only suggests 
that such a computer-supported retinal navigation focal laser 
therapy is feasible but also demonstrates an accuracy of 80% on 
an intention-to-treat basis and 96% on a per-protocol basis. In 
addition, patients reported significantly less treatment-related 
pain following navigated focal laser photocoagulation com-
pared to patients treated with a conventional laser. This may 
result in a higher acceptance of macular laser therapy in DME 
patients, which may help to improve treatment outcomes.
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